Medigene's Veregen® to be Launched in Serbia
(Thomson Reuters ONE) -
Medigene AG /
Medigene's Veregen® to be Launched in Serbia
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, April 16, 2013. Medigene AG (MDG, Frankfurt, Prime Standard)
announces that the company's marketing partner, Pharmanova d.o.o., will begin
commercializing Veregen(®) for the treatment of genital warts in Serbia on April
19, 2013. Serbia will be the fifth European country where Veregen(®) is
available, in addition to Germany, Austria, Switzerland, and Spain. Veregen(®)
is also available in the USA.
Pursuant to the agreement between Medigene and Pharmamova, Medigene received a
milestone payment upon marketing approval of the drug and is entitled to future
sales milestone payments. Moreover, Medigene will receive a double-digit
percentage of the Veregen(®) sales revenue as royalties and will generate
further income from the sale of finished product supply to Pharmanova.
The market launch of Veregen(®) in Serbia will take place during a conference on
sexually transmitted diseases (with special reference on HPV infections) that
has been organized by Pharmanova in Belgrade on April 19, 2013. During this
symposium, a number of renowned experts in the fields of dermatology and
gynecology will give lectures in front of a large audience of practitioners and
press representatives.
There are several market approvals and product launches of Veregen(®) in
additional countries expected in 2013. Medigene has entered into several
Veregen(®) marketing partnerships across Europe, Asia, and America and is
planning to continue this global licensing strategy to further leverage the
product's market potential.
About Veregen(®): Veregen(®), an ointment used in the topical treatment of
external genital warts, contains a catechin concentrate based on a defined
extract obtained from green tea leaves. Since 2010, Veregen(®) (Sinecatechins
15% ointment) has been recommended in the US Department of Health and Human
Services Center for Disease Control and Prevention's Sexually Transmitted
Diseases Treatment Guidelines as a possible option for treating genital warts.
Sinecatechins 10% & 15% ointment (Veregen(®)) was recently also included in the
European Guideline for the Management of Anogenital Warts.
About Pharmanova: Pharmanova is a privately owned Serbian pharmaceutical
company, with annual sales of over three million packages. Pharmanova is one of
the biggest producers of herbal medicines and reputable drugs and dietary
products in Serbia, and employs over 170 people. Pharmanova is seeking to
leverage its leading position in Serbia, and to expand into new markets, with
the addition of Veregen(®) ointment to its product portfolio. For further
information about Pharmanova please visit http://www.pharmanova.com/
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from a
marketed product (Veregen(®)), which is distributed by partner companies.
Medigene has two drug candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®),
and is developing an innovative vaccine technology. For more information,
please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF:
http://hugin.info/132073/R/1693117/556444.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1693117]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Destiny Media Announces Q2 ResultsDatum: 16.04.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 249241
Anzahl Zeichen: 5391
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 162 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene's Veregen® to be Launched in Serbia"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
